14286-19 Beach Blvd #270
Jacksonville, FL 32250
(904) 834-2665Espero Pharmaceuticals, Inc. was formerly a specialty pharmaceutical company focusing on compounds with proven safety and efficacy administered via novel delivery solutions in the cardiovascular and other specialty therapeutic categories. In 2016, the FDA approved GoNitro (nitroglycerin sublingual powder) which Espero Pharmaceuticals distributed in the U.S. market under an exclusive licensing agreement with G. Pohl-Boskamp GmbH & Co. KG, (Pohl Boskamp).
In June 2020, Rock Creek Advisors, LLC, serving as Espero's Financial Advisor announced it would be selling the assets of Espero BioPharma, Inc., including all intellectual properties, patent portfolio, formulations, URLs and trademarks associated with its names and brands as well as clinical trial results and related data to drug development.